NCT05178576 - A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy | Biotech Hunter

Timeline

Start Date

June 24, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions

Colon Cancer

Interventions

DRUG

Gevokizumab

120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)

DIAGNOSTIC_TEST

Signatera test

ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.

Trial Locations (5)

AHN Cancer Institute, Pittsburgh

Wake Forest Baptist Health, Winston-Salem

UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville

University of Iowa, Iowa City

Rutgers Cancer Institute of New Jersey, New Brunswick